|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gregers J, Gréen H, Christensen IJ,
Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B,
Schmiegelow K and Peterson C: Polymorphisms in the ABCB1 gene and
effect on outcome and toxicity in childhood acute lymphoblastic
leukemia. Pharmacogenomics J. 15:372–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neumann M, Vosberg S, Schlee C, Heesch S,
Schwartz S, Gökbuget N, Hoelzer D, Graf A, Krebs S, Bartram I, et
al: Mutational spectrum of adult T-ALL. Oncotarget. 6:2754–2766.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pui CH and Evans WE: Acute lymphoblastic
leukemia. N Engl J Med. 339:605–615. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mehta RG and Pezzuto JM: Discovery of
cancer preventive agents from natural products: From plants to
prevention. Curr Oncol Rep. 4:478–486. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Du QH, Peng C and Zhang H: Polydatin: A
review of pharmacology and pharmacokinetics. Pharm Biol.
51:1347–1354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Q, Tan Y, Zhang N and Yao F:
Polydatin prevents angiotensin II-induced cardiac hypertrophy and
myocardial superoxide generation. Exp Biol Med (Maywood). 2014.
View Article : Google Scholar
|
|
8
|
Dong M, Ding W, Liao Y, Liu Y, Yan D,
Zhang Y, Wang R, Zheng N, Liu S and Liu J: Polydatin prevents
hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes
and pressure-overload mouse models. Eur J Pharmacol. 746:186–197.
2015. View Article : Google Scholar
|
|
9
|
Ding W, Dong M, Deng J, Yan D, Liu Y, Xu T
and Liu J: Polydatin attenuates cardiac hypertrophy through
modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling
pathway. Am J Physiol Heart Circ Physiol. 307:H792–H802. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Q, Tan Y, Zhang N and Yao F:
Polydatin supplementation ameliorates diet-induced development of
insulin resistance and hepatic steatosis in rats. Mol Med Rep.
11:603–610. 2015.
|
|
11
|
Sun J, Qu Y, He H, Fan X, Qin Y, Mao W and
Xu L: Protective effect of polydatin on learning and memory
impairments in neonatal rats with hypoxic-ischemic brain injury by
up-regulating brain-derived neurotrophic factor. Mol Med Rep.
10:3047–3051. 2014.PubMed/NCBI
|
|
12
|
Ravagnan G, De Filippis A, Cartenì M, De
Maria S, Cozza V, Petrazzuolo M, Tufano MA and Donnarumma G:
Polydatin, a natural precursor of resveratrol, induces β-defensin
production and reduces inflammatory response. Inflammation.
36:26–34. 2013. View Article : Google Scholar
|
|
13
|
De Maria S, Scognamiglio I, Lombardi A,
Amodio N, Caraglia M, Cartenì M, Ravagnan G and Stiuso P:
Polydatin, a natural precursor of resveratrol, induces cell cycle
arrest and differentiation of human colorectal Caco-2 cell. J
Transl Med. 11:2642013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Zhuang Z, Meng Q, Jiao Y, Xu J
and Fan S: Polydatin inhibits growth of lung cancer cells by
inducing apoptosis and causing cell cycle arrest. Oncol Lett.
7:295–301. 2014.
|
|
15
|
Liu H, Zhao S, Zhang Y, Wu J, Peng H, Fan
J and Liao J: Reactive oxygen species-mediated endoplasmic
reticulum stress and mitochondrial dysfunction contribute to
polydatin-induced apoptosis in human nasopharyngeal carcinoma CNE
cells. J Cell Biochem. 112:3695–3703. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takemoto S, Mulloy JC, Cereseto A, Migone
TS, Patel BK, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihira S,
White JD, et al: Proliferation of adult T cell leukemia/lymphoma
cells is associated with the constitutive activation of JAK/STAT
proteins. Proc Natl Acad Sci USA. 94:13897–13902. 1997. View Article : Google Scholar
|
|
17
|
Alas S and Bonavida B: Rituximab
inactivates signal transducer and activation of transcription 3
(STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of
the interleukin 10 autocrine/paracrine loop and results in
down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
Cancer Res. 61:5137–5144. 2001.PubMed/NCBI
|
|
18
|
Wu EY, Smith MT, Bellomo G and Di Monte D:
Relationships between the mitochondrial transmembrane potential,
ATP concentration and cytotoxicity in isolated rat hepatocytes.
Arch Biochem Biophys. 282:358–362. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Medjkane S, Perichon M, Marsolier J,
Dairou J and Weitzman JB: Theileria induces oxidative stress and
HIF1 α activation that are essential for host leukocyte
transformation. Oncogene. 33:1809–1817. 2014. View Article : Google Scholar
|
|
20
|
Wang C and Youle RJ: The role of
mitochondria in apoptosis. Annu Rev Genet. 43:95–118. 2009.
View Article : Google Scholar
|
|
21
|
Gottlieb E, Armour SM, Harris MH and
Thompson CB: Mitochondrial membrane potential regulates matrix
configuration and cytochrome c release during apoptosis. Cell Death
Differ. 10:709–717. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herrera B, Alvarez AM, Sánchez A,
Fernández M, Roncero C, Benito M and Fabregat I: Reactive oxygen
species (ROS) mediates the mitochondrial-dependent apoptosis
induced by transforming growth factor (beta) in fetal hepatocytes.
FASEB J. 15:741–751. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meydan N, Grunberger T, Dadi H, Shahar M,
Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, et
al: Inhibition of acute lymphoblastic leukaemia by a Jak-2
inhibitor. Nature. 379:645–648. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu JY, Meng QH, Chong Y, Jiao Y, Zhao L,
Rosen EM and Fan S: Sanguinarine inhibits growth of human cervical
cancer cells through the induction of apoptosis. Oncol Rep.
28:2264–2270. 2012.PubMed/NCBI
|
|
25
|
Singh CK, Ndiaye MA and Ahmad N:
Resveratrol and cancer: Challenges for clinical translation.
Biochim Biophys Acta. 1852:1178–1185. 2015. View Article : Google Scholar
|
|
26
|
Francioso A, Mastromarino P, Masci A,
d'Erme M and Mosca L: Chemistry, stability and bioavailability of
resveratrol. Med Chem. 10:237–245. 2014. View Article : Google Scholar
|
|
27
|
Krasnow MN and Murphy TM: Polyphenol
glucosylating activity in cell suspensions of grape (Vitis
vinifera). J Agric Food Chem. 52:3467–3472. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daniel PT, Koert U and Schuppan J:
Apoptolidin: Induction of apoptosis by a natural product. Angew
Chem Int Ed Engl. 45:872–893. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Circu ML and Aw TY: Glutathione and
modulation of cell apoptosis. Biochim Biophys Acta. 1823:1767–1777.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qu K, Shen NY, Xu XS, Su HB, Wei JC, Tai
MH, Meng FD, Zhou L, Zhang YL and Liu C: Emodin induces human T
cell apoptosis in vitro by ROS-mediated endoplasmic reticulum
stress and mitochondrial dysfunction. Acta Pharmacol Sin.
34:1217–1228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choi YJ, Li X, Hydbring P, Sanda T,
Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer
H and Sicinski P: The requirement for cyclin D function in tumor
maintenance. Cancer Cell. 22:438–451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang K, Hitomi M and Stacey DW: Variations
in cyclin D1 levels through the cell cycle determine the
proliferative fate of a cell. Cell Div. 1:322006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vainchenker W and Constantinescu SN:
JAK/STAT signaling in hematological malignancies. Oncogene.
32:2601–2613. 2013. View Article : Google Scholar
|
|
37
|
James C, Ugo V, Le Couédic JP, Staerk J,
Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R,
Bennaceur-Griscelli A, et al: A unique clonal JAK2 mutation leading
to constitutive signalling causes polycythaemia vera. Nature.
434:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Levine RL, Wadleigh M, Cools J, Ebert BL,
Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et
al: Activating mutation in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia, and myeloid metaplasia with
myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lu M, Wang J, Li Y, Berenzon D, Wang X,
Mascarenhas J, Xu M and Hoffman R: Treatment with the Bcl-xL
inhibitor ABT-737 in combination with interferon α specifically
targets JAK2V617F-positive polycythemia vera hematopoietic
progenitor cells. Blood. 116:4284–4287. 2010. View Article : Google Scholar : PubMed/NCBI
|
